Skip to search formSkip to main contentSkip to account menu

lestaurtinib

Known as: 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- 
A drug being studied in the treatment of acute leukemias and some other types of cancer. It binds to a protein that is present on the surface of some… 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (2)

CEP-701KT-5555

Broader (1)

Carbazoles
DDR1 protein, humanNCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase InhibitionVascular Endothelial Growth Factor Receptor 2, human

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect
Internal tandem duplication (ITD) mutation of the FLT3 receptor tyrosine kinase ( FLT3/ITD ) is one of the most common gene… 
2014
2014
Crystal Structures of PRK1 in Complex with the Clinical Compounds Lestaurtinib and Tofacitinib Reveal Ligand Induced Conformational Changes
Protein kinase C related kinase 1 (PRK1) is a component of Rho-GTPase, androgen receptor, histone demethylase and histone… 
2014
2014
A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience
Activating mutations of the receptor tyrosine kinase FLT3 are seen at diagnosis in one-third of younger adults with acute myeloid… 
Highly Cited
2011
Highly Cited
2011
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Acute myeloid leukemia (AML) is a hematologic malignancy with a poor prognosis. Approximately one quarter of the patients with… 
2011
2011
Rethinking bioactivity of FLT3 inhibitors.
FLT3 inhibition has emerged as an attractive concept to overcome the dismal prognosis of FLT3 mutated AML patients. Sato and… 
2011
2011
The Efficacy of the FLT3 Inhibitor Lestaurtinib in AML Depends on Adequate Plasma Inhibitory Activity (PIA), and Is Unaffected by Rising FLT Ligand Levels: An Update of the NCRI AML15 & 17 Trials
Abstract 421 The receptor tyrosine kinase FLT3 remains the subject of intense clinical interest as a therapeutic target in AML… 
Review
2010
Review
2010
FLT3 inhibitors for the treatment of acute myeloid leukemia.
The fms-like receptor tyrosine kinase-3 (FLT3), which is important for the normal development of hematopoietic stem cells and… 
2009
2009
Lestaurtinib FLT3 Inhibitory Activity Is Modulated by Concomitant Azole Therapy and May Influence Relapse Risk.
Abstract 789 Activating mutations of the receptor tyrosine kinase FLT3 occur in approximately one-third of adults with AML and… 
2008
2008
Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication
FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML… 
2005
2005
Pharmacokinetic and Pharmacodynamic Studies of Lestaurtinib (CEP-701) and PKC-412: Cytotoxicity Is Often Dependent on Non-FLT3-Mediated Effects.
We undertook a study to compare two small molecule FLT3 inhibitors, CEP-701(lestaurtinib) and PKC-412. Both compounds have been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)